For research use only; not for diagnostic procedures. All products to be used in accordance with applicable laws and regulations including without limitation, consumption & disposal requirements under European REACH regulations (EC 1907/2006).
Formats:
Features:
AlphaLISA technology allows the detection of molecules of interest in buffer, cell culture media, serum and plasma in a highly sensitive, quantitative, reproducible and user-friendly mode. In an AlphaLISA assay, a Biotinylated Anti-Analyte Antibody binds to the Streptavidin-coated Alpha Donor beads, while another Anti-Analyte Antibody is conjugated to AlphaLISA Acceptor beads. In the presence of the analyte, the beads come into close proximity. The excitation of the Donor beads provokes the release of singlet oxygen molecules that triggers a cascade of energy transfer in the Acceptor beads, resulting in a sharp peak of light emission at 615 nm.
CD276 (Cluster of Differentiation 276, or B7-H3) is a type I transmembrane protein belonging to the B7 family of co-stimulatory proteins (e.g., B7-1, or CD80). It signals through CD28 family molecules such as CD28 and CTLA4. It is expressed ubiquitously, such as dendritic cells derived from monocytes, epithelial cells of sinonasal tissue, extravillous trophoblast cells and Hofbauer cells of the placenta. It is an immune checkpoint molecule, involved in the regulation of T-cell-mediated immune response. It is expressed by some solid tumours, as a biomarker for detection of neuroblastoma cells and is the target of anticancer therapy.
| Assay Target | CD276 |
|---|---|
| Assay Target Class | Protein |
| Automation Compatible | Yes |
| Detection Method | Alpha |
| Product Brand Name | AlphaLISA |
| Shipping Condition | Blue Ice |
| Therapeutic Area | Oncology |
| Unit Size | 500 Assay Points |
The introduction of enzyme-linked immunosorbent assays (ELISAs) in the early 1970’s offered researchers a non-radiometric immunoassay platform without compromising sensitivity. Over the last 50 years scientists have made huge strides in disease research and drug discovery and a demand for greater assay throughput and sensitivity has evolved. In response, more robust immunoassays have been developed to address some of the limitations of the standard, colorimetric ELISA.
Find out about the most common limitations of traditional ELISAs and how different ELISA alternative technologies address these limitations.
A variety of chemotherapeutic drugs with different modes of action have been developed and tested as potential therapies for colorectal cancer. Characterizing the effects of potential drugs with different modes of action is a key part of the process.
In this application note you will learn:
One approach to immunotherapy is the modulation of immune checkpoints that are critical in regulating the degree and duration of immune system responses and preventing autoimmunity.
In this application note, you will learn:
Immune checkpoints serve a critical role in the immune system to prevent autoimmunity and manage the degree and duration of an immune response. Cytotoxic T-Lymphocyte-associated protein 4 (CTLA-4 or CD152) is an inhibitory transmembrane protein involved in an immune checkpoint of significant interest for therapeutic development. When CTLA-4 is expressed and competes with CD28, the immune system response is downregulated. As a result of this immune system response balance, immune checkpoints provide an opportunity for therapeutic intervention to modulate immune system activity.
There is a high demand for new drugs to block CTLA-4 and modulate immune system activity. In this application note, we demonstrate how to screen for novel CTLA-4 blocking drugs by utilizing the AlphaLISA CTLA-4/CD80 binding assay.
Protocol for performing an AlphaLISA human CD276 detection and quantitation assay
List Price : USD70.0
OptiPlate-384, White Opaque 384-well Microplate, Case 50
List Price : USD307.0
AlphaPlate-384, Light gray, untreated, Case of 50
List Price : USD567.0
